AR066848A1 - Polipeptidos, dominios variables de anticuerpos y antagonistas del receptor de tipo 1 del factor de necrosis tumoral (tnfr1) - Google Patents

Polipeptidos, dominios variables de anticuerpos y antagonistas del receptor de tipo 1 del factor de necrosis tumoral (tnfr1)

Info

Publication number
AR066848A1
AR066848A1 ARP080102363A ARP080102363A AR066848A1 AR 066848 A1 AR066848 A1 AR 066848A1 AR P080102363 A ARP080102363 A AR P080102363A AR P080102363 A ARP080102363 A AR P080102363A AR 066848 A1 AR066848 A1 AR 066848A1
Authority
AR
Argentina
Prior art keywords
antagonists
polypeptides
variable domains
tnfr1
antibodies
Prior art date
Application number
ARP080102363A
Other languages
English (en)
Original Assignee
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0724331.4A external-priority patent/GB0724331D0/en
Application filed by Domantis Ltd filed Critical Domantis Ltd
Publication of AR066848A1 publication Critical patent/AR066848A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

Dominios variables simples (dAb) de polipéptidos y anticuerpos anti-TNFR1 que son resistentes a la degradacion por una proteasa, así como a los antagonistas que comprende estos. Los polipéptidos, dAb y antagonistas son utiles como terapéuticos y/o profilácticos probablemente para combatir las proteasas cuando se administran a un paciente, por ejemplo por administracion pulmonar, administracion oral, suministro al pulmon y suministro al tracto (Gl) de un paciente, así como para tratar enfermedades inflamatorias tal como artritis o COPD.
ARP080102363A 2007-06-06 2008-06-04 Polipeptidos, dominios variables de anticuerpos y antagonistas del receptor de tipo 1 del factor de necrosis tumoral (tnfr1) AR066848A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93363207P 2007-06-06 2007-06-06
GBGB0724331.4A GB0724331D0 (en) 2007-12-13 2007-12-13 Compositions for pulmonary delivery

Publications (1)

Publication Number Publication Date
AR066848A1 true AR066848A1 (es) 2009-09-16

Family

ID=39791116

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP080102363A AR066848A1 (es) 2007-06-06 2008-06-04 Polipeptidos, dominios variables de anticuerpos y antagonistas del receptor de tipo 1 del factor de necrosis tumoral (tnfr1)
ARP080102362A AR066847A1 (es) 2007-06-06 2008-06-04 Polipeptidos, dominios variables de anticuerpos, anticuerpos y antagonistas que se unen al receptor de interleuquina-1 del tipo 1
ARP080102365A AR066850A1 (es) 2007-06-06 2008-06-04 Dominio variable simple de inmunoglobulina contra el factor de crecimiento endotelial vascular (vegf)

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP080102362A AR066847A1 (es) 2007-06-06 2008-06-04 Polipeptidos, dominios variables de anticuerpos, anticuerpos y antagonistas que se unen al receptor de interleuquina-1 del tipo 1
ARP080102365A AR066850A1 (es) 2007-06-06 2008-06-04 Dominio variable simple de inmunoglobulina contra el factor de crecimiento endotelial vascular (vegf)

Country Status (32)

Country Link
US (5) US8398979B2 (es)
EP (5) EP2162468A2 (es)
JP (3) JP2010530364A (es)
KR (4) KR20100018040A (es)
CN (4) CN101778865B (es)
AR (3) AR066848A1 (es)
AU (4) AU2008259590A1 (es)
BR (3) BRPI0813899A2 (es)
CA (6) CA2688434A1 (es)
CL (3) CL2008001676A1 (es)
CO (2) CO6251321A2 (es)
CR (2) CR11194A (es)
CY (1) CY1116762T1 (es)
DK (1) DK2162467T3 (es)
DO (1) DOP2009000268A (es)
EA (5) EA200901494A1 (es)
ES (1) ES2546943T3 (es)
HK (1) HK1138022A1 (es)
HR (1) HRP20151024T1 (es)
HU (1) HUE025899T2 (es)
IL (2) IL201398A0 (es)
MA (2) MA31403B1 (es)
MX (4) MX2009013137A (es)
NZ (1) NZ581372A (es)
PE (3) PE20090763A1 (es)
PL (1) PL2162467T3 (es)
PT (1) PT2162467E (es)
SG (2) SG182141A1 (es)
SI (1) SI2162467T1 (es)
TW (6) TW200902551A (es)
WO (3) WO2008149149A2 (es)
ZA (1) ZA200908470B (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
PL1888641T3 (pl) 2005-05-18 2012-05-31 Ablynx Nv Białka wiążące albuminę surowicy
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
NZ580530A (en) * 2007-06-06 2012-04-27 Domantis Ltd Anti vegf polypeptides, antibody variable domains and antagonists
CA2688434A1 (en) 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
US20100260853A1 (en) * 2007-12-13 2010-10-14 Amrik Basran Compositions for pulmonary delivery
AU2009237662A1 (en) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
PL2307454T3 (pl) 2008-06-25 2017-07-31 Esbatech, An Alcon Biomedical Research Unit Llc Trwałe i rozpuszczalne przeciwciała hamujące VEGF
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
AU2009319175A1 (en) * 2008-11-26 2010-06-03 Glaxo Group Limited Polypeptides, antibody variable domains & antagonists
WO2010081787A1 (en) 2009-01-14 2010-07-22 Domantis Limited IMPROVED TNFα ANTAGONISM, PROPHYLAXIS & THERAPY WITH REDUCED ORGAN NECROSIS
JP2012517818A (ja) * 2009-02-19 2012-08-09 グラクソ グループ リミテッド 改善された抗ｔｎｆｒ１ポリペプチド、抗体可変ドメインおよびアンタゴニスト
JP5766616B2 (ja) 2009-02-19 2015-08-19 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ 改良型抗血清アルブミン結合変異体
NZ595242A (en) 2009-02-19 2013-11-29 Glaxo Group Ltd Improved anti-serum albumin binding variants
EP2401298A1 (en) 2009-02-24 2012-01-04 Glaxo Group Limited Antigen-binding constructs
US20120107330A1 (en) 2009-07-16 2012-05-03 Adriaan Allart Stoop Antagonists, uses & methods for partially inhibiting tnfr1
IN2012DN00640A (es) 2009-07-16 2015-08-21 Glaxo Group Ltd
CA2777700A1 (en) * 2009-10-14 2011-04-21 Aileron Therapeutics, Inc. Improved peptidomimetic macrocycles
JP2013507978A (ja) 2009-10-27 2013-03-07 グラクソ グループ リミテッド 安定な抗ｔｎｆｒ１ポリペプチド、抗体可変ドメイン及びアンタゴニスト
WO2011095545A1 (en) 2010-02-05 2011-08-11 Ablynx Nv Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
EA201291009A1 (ru) 2010-05-20 2013-05-30 Глаксо Груп Лимитед Улучшенные связывающие варианты против сывороточного альбумина
JP2013538566A (ja) 2010-08-13 2013-10-17 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 改良された抗血清アルブミン結合変異体
KR20130055663A (ko) * 2010-08-20 2013-05-28 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 개선된 항-혈청 알부민 결합 변이체
PL2616489T3 (pl) 2010-09-16 2017-07-31 Baliopharm Ag Przeciwciało anty-huTNFR1
US20130266567A1 (en) 2010-12-01 2013-10-10 Haren Arulanantham Anti-serum albumin binding single variable domains
EP2670778A1 (en) * 2011-02-02 2013-12-11 Glaxo Group Limited Novel antigen binding proteins
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
SG10201811256QA (en) 2011-06-28 2019-01-30 Inhibrx Lp Serpin fusion polypeptides and methods of use thereof
EA028886B1 (ru) * 2011-07-27 2018-01-31 Глаксо Груп Лимитед ОТДЕЛЬНЫЕ ВАРИАБЕЛЬНЫЕ ДОМЕНЫ ПРОТИВ VEGF, СЛИТЫЕ С Fc-ДОМЕНАМИ
KR102162413B1 (ko) * 2011-08-17 2020-10-07 글락소 그룹 리미티드 변형된 단백질 및 펩티드
GB2497138A (en) * 2011-12-02 2013-06-05 Randox Lab Ltd Biomarkers for stroke and stroke subtype diagnosis.
EP3495387B1 (en) 2012-07-13 2021-09-01 Roche Glycart AG Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
WO2014111550A1 (en) 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
CN104936973A (zh) * 2013-01-31 2015-09-23 葛兰素集团有限公司 生产蛋白的方法
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
MA41374A (fr) * 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
BR112018013407A2 (pt) 2015-12-30 2018-12-18 Kodiak Sciences Inc anticorpos e conjugados dos mesmos
GB201617622D0 (en) * 2016-10-18 2016-11-30 VIB VZW and Universiteit Gent Means and methods to treat inflammation
RU2625010C1 (ru) * 2016-11-10 2017-07-11 Илья Петрович Приколаб Экспрессионный плазмидный вектор для экспрессии активной формы TNFR1-Fc и способ получения рекомбинантного белка
US11168139B2 (en) 2016-11-28 2021-11-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding domain, and polypeptide including conveying section
UY37651A (es) * 2017-03-31 2018-10-31 Swedish Orphan Biovitrum Ab Publ Polipéptido de unión al il-1r-i
AU2018359532B2 (en) * 2017-11-01 2024-03-28 Allogene Therapeutics, Inc. Modified caspase-9 polypeptides and methods of use thereof
EP3802831A4 (en) 2018-05-30 2022-07-27 Chugai Seiyaku Kabushiki Kaisha POLYPEPTIDE COMPRISING AN IL-1R1 BINDING DOMAIN AND A TRANSPORT FRACTION
EP3623798B1 (de) * 2018-09-13 2021-11-03 Euroimmun Medizinische Labordiagnostika AG Verfahren und vorrichtung zum erfassen und darstellen eines immunfluoreszenzbildes einer biologischen probe
EP3870331A1 (en) * 2018-10-25 2021-09-01 F. Hoffmann-La Roche AG Modification of antibody fcrn binding
CN111454366B (zh) * 2019-01-21 2023-06-16 中国科学院深圳先进技术研究院 一种融合蛋白及其应用
JP7315967B2 (ja) * 2019-01-31 2023-07-27 積水メディカル株式会社 生物学的試料中の遊離ａｉｍの免疫学的分析方法及び測定キット
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
EP4204094A1 (en) 2020-08-27 2023-07-05 Enosi Therapeutics Corporation Methods and compositions to treat autoimmune diseases and cancer
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
CN115181751A (zh) * 2021-04-02 2022-10-14 苏州博腾生物制药有限公司 靶向白蛋白的嵌合抗原受体及其使用方法
CN114657162B (zh) * 2022-03-04 2023-06-16 华南理工大学 一种具有血管内皮细胞保护功能的抗氧化五肽及其应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
WO1989007142A1 (en) 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies
AU4308689A (en) 1988-09-02 1990-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
EP0546073B1 (en) 1990-08-29 1997-09-10 GenPharm International, Inc. production and use of transgenic non-human animals capable of producing heterologous antibodies
ES2155822T3 (es) 1990-12-06 2001-06-01 Affymetrix Inc Compuestos y su utilizacion en una estrategia de sintesis binaria.
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5702892A (en) 1995-05-09 1997-12-30 The United States Of America As Represented By The Department Of Health And Human Services Phage-display of immunoglobulin heavy chain libraries
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
NZ536216A (en) * 1996-02-09 2006-08-31 Abbott Biotech Ltd Use of an isolated antibody D2E7 for the treatment of a disorder in which TNF(alpha) activity is detrimental
EP1908832B1 (en) 1997-07-07 2012-12-26 Medical Research Council A method for increasing the concentration of a nucleic acid molecule
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
EP1078051B1 (en) 1998-05-13 2007-12-12 Domantis Limited Phage-display system for the selection of correctly folded proteins
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
CA2399809A1 (en) 2000-02-03 2001-08-09 Domantis Limited Combinatorial protein domains
CA2399388A1 (en) 2000-02-11 2001-08-16 Michael J. Lenardo Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
US7265210B2 (en) * 2000-09-15 2007-09-04 Genentech, Inc. Anti-PRO9821 antibodies
EP2338512A1 (en) 2000-11-28 2011-06-29 MedImmune, LLC Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
WO2004058821A2 (en) * 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
EP1399484B1 (en) 2001-06-28 2010-08-11 Domantis Limited Dual-specific ligand and its use
WO2004003019A2 (en) 2002-06-28 2004-01-08 Domantis Limited Immunoglobin single variant antigen-binding domains and dual-specific constructs
GB0118689D0 (en) * 2001-08-01 2001-09-19 Psimedica Ltd Pharmaceutical formulation
US20080108560A1 (en) 2002-03-05 2008-05-08 Eli Lilly And Company Heterologous G-Csf Fusion Proteins
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
CA2496834C (en) 2002-09-06 2014-03-18 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component c5
MEP32508A (en) 2002-09-06 2010-10-10 Amgen Inc Therapeutic human anti-il-1r1 monoclonal antibody
JP2006520584A (ja) 2002-11-08 2006-09-14 アブリンクス エン．ヴェー． 安定化単一ドメイン抗体
GB0230203D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
US20060104968A1 (en) * 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
PT1639011E (pt) * 2003-06-30 2009-01-20 Domantis Ltd Anticorpos (dab) de domínio único peguilados
BRPI0507026A (pt) 2004-02-09 2007-04-17 Human Genome Sciences Inc proteìnas de fusão de albumina
PL1737962T3 (pl) 2004-03-24 2011-02-28 Domantis Ltd Uniwersalny lider GAS1
AU2005299701B2 (en) * 2004-10-21 2011-11-17 Genentech, Inc. Method for treating intraocular neovascular diseases
GB0521621D0 (en) * 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
AU2005311101B8 (en) * 2004-12-02 2011-03-03 Domantis Limited Anti-IL-IRI single domain antibodies and therapeutic uses
TW200736276A (en) * 2005-12-01 2007-10-01 Domantis Ltd Competitive domain antibody formats that bind interleukin 1 receptor type 1
EP1957536A2 (en) 2005-12-01 2008-08-20 Domantis Limited Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
PT2068889T (pt) 2006-08-10 2020-01-30 Roy C Levitt Anakinra para uso no tratamento da síndrome da bronquiolite obliterante
JP2010507624A (ja) * 2006-10-27 2010-03-11 アブリンクス エン．ヴェー． ポリペプチド及びタンパク質の鼻内送達
CA2688434A1 (en) 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
NZ580530A (en) 2007-06-06 2012-04-27 Domantis Ltd Anti vegf polypeptides, antibody variable domains and antagonists

Also Published As

Publication number Publication date
IL202204A0 (en) 2010-06-16
EP2162467A2 (en) 2010-03-17
JP2010529841A (ja) 2010-09-02
HK1138022A1 (en) 2010-08-13
CL2008001676A1 (es) 2008-11-21
US20110256122A1 (en) 2011-10-20
WO2008149149A3 (en) 2009-04-02
AU2008259590A1 (en) 2008-12-11
JP5325211B2 (ja) 2013-10-23
WO2008149148A2 (en) 2008-12-11
CN104311663B (zh) 2018-11-02
CL2008001673A1 (es) 2008-11-21
MA31403B1 (fr) 2010-05-03
PT2162467E (pt) 2015-10-29
EA200901300A1 (ru) 2010-06-30
EA200901491A1 (ru) 2010-08-30
CA2683823A1 (en) 2008-12-11
CA2683791A1 (en) 2008-12-11
CN104311663A (zh) 2015-01-28
CR11195A (es) 2010-05-24
CL2008001674A1 (es) 2008-11-21
JP2010530364A (ja) 2010-09-09
TW200907128A (en) 2009-02-16
BRPI0812268A2 (pt) 2019-09-10
US20100266616A1 (en) 2010-10-21
KR20100041746A (ko) 2010-04-22
TW200911832A (en) 2009-03-16
CA2688447A1 (en) 2008-12-11
SG182141A1 (en) 2012-07-30
MX2009013138A (es) 2010-04-30
CN101802004A (zh) 2010-08-11
CA2688447C (en) 2016-11-08
PE20090763A1 (es) 2009-07-10
EP2162468A2 (en) 2010-03-17
KR20100040841A (ko) 2010-04-21
AU2008259516A1 (en) 2008-12-11
WO2008149150A3 (en) 2009-06-25
EP2746290A3 (en) 2014-09-10
EA200901494A1 (ru) 2010-06-30
JP5444215B2 (ja) 2014-03-19
EP2746291A2 (en) 2014-06-25
CN101778865B (zh) 2016-11-09
TW200902551A (en) 2009-01-16
KR20100018040A (ko) 2010-02-16
US8398979B2 (en) 2013-03-19
CO6251322A2 (es) 2011-02-21
MX2009013211A (es) 2010-04-09
EP2164867A2 (en) 2010-03-24
CO6251321A2 (es) 2011-02-21
CR11194A (es) 2010-06-28
US20120134982A1 (en) 2012-05-31
EA201100546A1 (ru) 2011-12-30
TW200911834A (en) 2009-03-16
EP2746290A2 (en) 2014-06-25
TW200918088A (en) 2009-05-01
HUE025899T2 (en) 2016-05-30
NZ581372A (en) 2012-02-24
EP2162467B1 (en) 2015-07-22
SI2162467T1 (sl) 2015-11-30
PE20090322A1 (es) 2009-04-20
AU2008259514B2 (en) 2014-05-15
TW200911831A (en) 2009-03-16
US20090148437A1 (en) 2009-06-11
MX2009012967A (es) 2010-04-01
ES2546943T3 (es) 2015-09-30
WO2008149148A3 (en) 2009-04-02
EA018129B1 (ru) 2013-05-30
US20100247515A1 (en) 2010-09-30
MA31668B1 (fr) 2010-09-01
IL201398A0 (en) 2010-05-31
KR101604274B1 (ko) 2016-03-17
BRPI0812795B1 (pt) 2019-12-03
JP2010530220A (ja) 2010-09-09
EP2746291A3 (en) 2014-09-03
CY1116762T1 (el) 2017-03-15
PE20090323A1 (es) 2009-04-20
HRP20151024T1 (hr) 2015-11-06
EP2746291B1 (en) 2019-08-14
EA018723B1 (ru) 2013-10-30
CA2688434A1 (en) 2008-12-11
AR066847A1 (es) 2009-09-16
AU2008259515A1 (en) 2008-12-11
BRPI0812795C1 (pt) 2021-05-25
CA2688456A1 (en) 2008-12-11
CA2688433A1 (en) 2008-12-11
BRPI0813899A2 (pt) 2019-09-24
BRPI0812795B8 (pt) 2020-01-28
BRPI0812795A2 (pt) 2014-12-02
CN101883788A (zh) 2010-11-10
AU2008259514A1 (en) 2008-12-11
EP2746290B1 (en) 2019-08-14
WO2008149149A2 (en) 2008-12-11
ZA200908470B (en) 2011-02-23
EA200901495A1 (ru) 2010-10-29
DK2162467T3 (en) 2015-08-24
PL2162467T3 (pl) 2015-12-31
DOP2009000268A (es) 2010-02-28
AR066850A1 (es) 2009-09-16
SG182151A1 (en) 2012-07-30
CN101778865A (zh) 2010-07-14
WO2008149150A2 (en) 2008-12-11
KR20100021642A (ko) 2010-02-25
MX2009013137A (es) 2010-04-30

Similar Documents

Publication Publication Date Title
AR066848A1 (es) Polipeptidos, dominios variables de anticuerpos y antagonistas del receptor de tipo 1 del factor de necrosis tumoral (tnfr1)
AR066849A1 (es) Polipeptidos, dominios variables de anticuerpos y antagonistas del factor de crecimiento endotelial vascular (vegf)
WO2008149144A3 (en) Polypeptides, antibody variable domains and antagonists
MX2011008799A (es) Polipeptidos, dominios variables de anticuerpos, y antagonistas anti-tnfr1 mejorados.
TW200744642A (en) Novel peptides for use in the treatment of obesity
AU2011332810A8 (en) Anti-IL-6 antibodies for the treatment of oral mucositis
TW200637614A (en) Bendamustine pharmaceutical compositions
BRPI0407001A (pt) Método para aumentar a estabilidade de uma proteìna purificada, uso de uma proteìna ligante sìtio-especìfica ativa, método para aumentar a produção de uma proteìna recombinante e composição farmacêutica
BR112015004734A2 (pt) proteínas de fusão para tratar uma síndrome metabólica
ATE543804T1 (de) Neue verbindungen
BR112021009856A8 (pt) Terapia para tratamento do câncer com uma administração intratumoral e / ou intravenosa de um mva recombinante que codifica 4-1bbl (cd137l) e / ou cd40l
MX2021005346A (es) Constructos de suministro para transcitosis y metodos relacionados.
AR078763A1 (es) Polipeptidos anti factor de necrosis tumoral 1 (anti-tnfr1) estables, dominios variables de anticuerpos y antagonistas
EA201070725A1 (ru) Бис-пиридилпиридоны как антагонисты рецептора 1 меланинконцентрирующего гормона
EA200970127A1 (ru) Модулятор рецепторов глюкокортикостероидов и способы его применения
RS52672B (en) DEFERRED-RELEASE TREATMENT OF RHEUMATOID DISEASES
BR112022009798A2 (pt) Vírus mva recombinante para administração intratumoral e/ou intravenosa para tratamento de câncer
DOP2009000265A (es) Polipeptidos, dominios variables de anticuerpos y antagonistas
DK1748785T3 (da) Peptider til modulering af bruskhomeostase
EA202092547A1 (ru) Связанные со слитым пептидом, содержащим глюкагонподобный пептид 1 (glp-1), циклические пептидные тирозинтирозиновые конъюгаты и их применение
RU2010126053A (ru) Применение аналогов соматостатина при менингиоме
MX2020009877A (es) Péptidos neutralizantes de miotoxina.
UA112751U (xx) Спосіб лікування хронічного обструктивного захворювання легень у поєднанні з остеоартритом
CY1115559T1 (el) Αντισωματα εναντι αμυλοειδους-βητα πεπτιδιου
TH173387A (th) โพลีเปปไทด์ปัจจัยการเจริญเติบโตที่คล้ายอินซูลินที่ถูกรักษาสภาพ

Legal Events

Date Code Title Description
FA Abandonment or withdrawal